Approach to High-Risk Multiple Myeloma.

Authors :: Chen X
Varma G
Davies F
Morgan G
Source :: Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2024 Apr; Vol. 38 (2), pp. 497-510. Date of Electronic Publication: 2024 Jan 08.
Publication Year :: 2024
Abstract: Improving the outcome of high-risk myeloma (HRMM) is a key therapeutic aim for the next decade. To achieve this aim, it is necessary to understand in detail the genetic drivers underlying this clinical behavior and to target its biology therapeutically. Advances have already been made, with a focus on consensus guidance and the application of novel immunotherapeutic approaches. Cases of HRMM are likely to have impaired prognosis even with novel strategies. However, if disease eradication and minimal disease states are achieved, then cure may be possible.<br />Competing Interests: Disclosures X. Chen, G. Varma declare no related conflict of interests.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)